INSMED Inc · Exercise / conversion · Common Stock

What does this filing report?

An SEC Form 4 filing for INSMED Inc records an exercise / conversion involving Common Stock on December 18, 2025. The reported quantity was 6,259. The filing date is December 19, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Filing footnotes & remarks

F1

This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2

This is the weighted average sales price representing 350 shares sold at prices ranging from $161.72 to $162.69 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F3

This is the weighted average sales price representing 1,465 shares sold at prices ranging from $162.72 to $163.62 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F4

This is the weighted average sales price representing 447 shares sold at prices ranging from $163.75 to $164.73 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F5

This is the weighted average sales price representing 697 shares sold at prices ranging from $164.83 to $165.67 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F6

This is the weighted average sales price representing 1,783 shares sold at prices ranging from $166.00 to $166.99 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F7

This is the weighted average sales price representing 1,431 shares sold at prices ranging from $167.00 to $167.95 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F8

This is the weighted average sales price representing 2,175 shares sold at prices ranging from $168.01 to $169.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F9

This is the weighted average sales price representing 1,938 shares sold at prices ranging from $169.01 to $170.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F10

This is the weighted average sales price representing 362 shares sold at prices ranging from $170.02 to $170.91 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F11

This is the weighted average sales price representing 51 shares sold at prices ranging from $171.09 to $171.35 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F12

The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.